Umar Abbasi, Mohd Zaid Khan, Mahak Fatima, Garima Gupta, Nagashekhara Molugulu, Amirhossein Sahebkar, Mohammed A S Abourehab, Prashant Kesharwani
{"title":"Exploring the potential of nanoemulgels for dermatological disorders.","authors":"Umar Abbasi, Mohd Zaid Khan, Mahak Fatima, Garima Gupta, Nagashekhara Molugulu, Amirhossein Sahebkar, Mohammed A S Abourehab, Prashant Kesharwani","doi":"10.1080/1061186X.2025.2497368","DOIUrl":"https://doi.org/10.1080/1061186X.2025.2497368","url":null,"abstract":"<p><strong>Background and purpose: </strong>Nanoemulgels are an advanced innovation in dermatological formulations designed to treat various skin diseases. By combining the advantages of hydrogels and nanoemulsions, these hybrid systems optimise drug delivery and improve therapeutic results. Because of their nanoscale droplets, nanoemulsions improve solubility by increasing surface area and stability and bioavailability of medications.</p><p><strong>Methods and results: </strong>When embedded in a hydrogel matrix, their transformation into nanoemulgels, provide regulated and prolonged drug release, ensuring sustained therapeutic action. The ability of nanoemulgels to penetrate deeply into the layers of skin and get past obstacles like the stratum corneum to improve drug penetration and efficacy makes them highly effective in dermatology. Since the gel component helps to reduce the surface and interfacial tension and a rise in spreading coefficient along with the viscosity. The benefits of using NEGs for external use include their thixotropic, greaseless, readily dispersed properties, longer shelf life, emollient, effortlessly removed, non-staining clear, cosmetically attractive and environment friendly characteristics.</p><p><strong>Conclusions: </strong>By providing an overview of research on nanoemulgels' permeability mechanisms, pharmacokinetics, uses, properties and the difficulties involved in topical drug delivery for skin disorders, this review emphasises the potential of these materials as topical drug delivery systems in dermatology.</p>","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-23"},"PeriodicalIF":4.3,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144024151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chuanyu Zhuang, Minji Kang, Jihun Oh, Chowon Lee, Minhyung Lee
{"title":"Engineered extracellular vesicle with RAGE-antagonist peptide for delivery of anti-miRNA155 oligonucleotides to inflammatory lung cells.","authors":"Chuanyu Zhuang, Minji Kang, Jihun Oh, Chowon Lee, Minhyung Lee","doi":"10.1080/1061186X.2025.2500040","DOIUrl":"https://doi.org/10.1080/1061186X.2025.2500040","url":null,"abstract":"<p><p>Acute lung injury (ALI) is an inflammatory lung disease. In lungs afflicted with ALI, microRNA-155 (miR-155) is over-expressed, inducing pro-inflammatory cytokines by inhibition of suppressor of cytokine signaling 1 (SOCS1). In addition, receptors for advanced glycation end-products (RAGEs) are activated, facilitating the expression of pro-inflammatory cytokines. Therefore, anti-miRNA-155 oligonucleotides (AMO155) and a RAGE-antagonist peptide (RAP) have been suggested as effective therapeutics of ALI. In this study, extracellular vesicles (EVs) were developed as a carrier of AMO155 and the RAP for a combination therapy of ALI. RAP-engineered EVs (RAP-EVs) were produced by the expression of a recombinant RAP-Lamp2b fusion protein on the surface. Then, cholesterol-modified AMO155 (AMO155c) was loaded onto the RAP-EV. <i>In vitro</i> assays showed that the RAP-EV delivered AMO155c as efficiently as unmodified-EV (Unmod-EV). For <i>in vivo</i> animal experiments, AMO155c-loaded EVs (AMO155c/EVs) were administrated into the ALI models by intratracheal instillation. The results showed that the AMO155c/RAP-EV induced SOCS1 and decreased RAGE expression more efficiently than the control systems. Compared to the controls, the inflammatory responses, such as pro-inflammatory cytokines, were effectively reduced by the AMO155c/RAP-EV. The results indicated that the RAP-EV could be an efficient carrier for the combination therapy of the RAP and AMO155c.</p>","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-12"},"PeriodicalIF":4.3,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Emodin nanocrystals enhanced mucus penetration and ameliorated bleomycin-induced pulmonary fibrosis by pulmonary delivery.","authors":"Chenghao Zhang, Yihua Wang, Xinran Cui, Qing Zhang, Huijing Cong, Jiaxin Liu, Jinmei Ren, Jingling Tang","doi":"10.1080/1061186X.2025.2497369","DOIUrl":"https://doi.org/10.1080/1061186X.2025.2497369","url":null,"abstract":"<p><p>Pulmonary fibrosis (PF) is a progressive interstitial disease characterised by extracellular matrix deposition and destruction of lung tissue structure. Emodin (Emo) is a natural active compound with anti-inflammatory and antioxidant properties. The initiation of PF is prevented by reducing oxidative stress-induced damage to alveolar epithelial cells.\" to meet the word count requirement. However, Emo is featured low water solubility, a rapid metabolic rate and low oral bioavailability, which limit its application in the treatment of PF. Therefore, this study formulated emodin as nanocrystals (Emo-NCs) and delivered Emo directly to the lesion site <i>via</i> pulmonary delivery to enhance drug efficacy. The Emo-NCs exhibited a square crystal structure with particle sizes suitable for pulmonary absorption and an appropriate polydispersity index. They released 99.38% over 48 h and significantly improved permeability efficiency in simulated pulmonary mucus. The ability of Emo-NCs to inhibit abnormal fibroblast proliferation and oxidative damage was significantly enhanced compared with Emo. In contrast to the BLM group, the inflammatory cells in the lung tissue sections of the Emo-NCs group were significantly reduced, the alveolar structure was largely restored, and no evident collagen fibre deposition was observed. In summary, Emo-NCs could serve as a viable delivery system for site-specific treatment of PF.</p>","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-11"},"PeriodicalIF":4.3,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ying Fan, Chuli Liao, Jie Li, Meiling Wu, Jie Liu, Feng Li, Wen Wu
{"title":"S-nitrosoglutathione releasing nano-micron combination hydrogel enhances cutaneous wound healing via promoting angiogenesis and collagen deposition.","authors":"Ying Fan, Chuli Liao, Jie Li, Meiling Wu, Jie Liu, Feng Li, Wen Wu","doi":"10.1080/1061186X.2025.2489983","DOIUrl":"https://doi.org/10.1080/1061186X.2025.2489983","url":null,"abstract":"<p><p>Nitric oxide (NO) is essential for wound healing, promoting angiogenesis and collagen deposition. This study investigates a novel dual-matrix nanocomposite hydrogel incorporating S-nitrosoglutathione (GSNO), a physiological NO donor, to enhance cutaneous wound healing. GSNO was encapsulated in ammonio methacrylate copolymer nanoparticles and embedded in an alginate-based matrix, achieving controlled NO release. GSNO-loaded nanoparticles were prepared using solvent displacement and solvent evaporation methods, resulting in spherical, well-distributed and positively charged particles. These nanoparticles were cross-linked with negatively charged alginic acid to form a nanocomposite hydrogel. The hydrophobic nanoparticles protected GSNO from degradation, while the hydrophilic alginate matrix sustained the release of active GSNO for up to 10 h, promoting haemostasis and maintaining a moist wound environment. The hydrogel exhibited good biocompatibility in human fibroblasts and significantly enhanced wound repair by promoting fibroblast formation, neovascularisation and collagen deposition, as demonstrated by haematoxylin and eosin staining and Masson's trichrome staining. In conclusion, the GSNO-loaded nanocomposite hydrogel significantly accelerated the healing process by enhancing angiogenesis and collagen deposition, offering a promising strategy for improving wound healing.</p>","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-9"},"PeriodicalIF":4.3,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Novel therapeutic approaches for non-small cell lung cancer: an updated view.","authors":"Niloufar Orooji, Shabnam Babaei, Manouchehr Fadaee, Hajar Abbasi-Kenarsari, Majid Eslami, Tohid Kazemi, Bahman Yousefi","doi":"10.1080/1061186X.2025.2489986","DOIUrl":"10.1080/1061186X.2025.2489986","url":null,"abstract":"<p><p>Non-small cell lung cancer (NSCLC) continues to be one of the leading causes of cancer-related mortality globally. Most patients who undergo surgical procedures may encounter distant metastasis or local recurrence, necessitating supplementary treatments such as radiation therapy, chemotherapy, or targeted therapy as adjuvant alternatives. Recent advancements in molecular biology and immunotherapy have paved the way for innovative therapeutic approaches that target specific genetic mutations and promote the immune response against tumour cells. This review explores emerging therapies, including targeted therapies such as tyrosine kinase inhibitors (TKIs) for actionable mutations (e.g., EGFR, ALK, ROS1), as well as the role of immune checkpoint inhibitors (ICIs) that employ the body's immune system to combat cancer. Additionally, we discuss the potential of exosome therapies, as well as promising nanotherapeutic options for the treatment of NSCLC. This study attempts to provide a thorough overview of the changing landscape of NSCLC treatment and its implications for enhancing patient outcomes by presenting these innovative techniques.</p>","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-16"},"PeriodicalIF":4.3,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143788397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The potential use of bacteria and their derivatives as delivery systems for nanoparticles in the treatment of cancer.","authors":"Shiva Ahmadishoar, Samaa Mones Saeed, Morug Salih Mahdi, Waam Mohammed Taher, Mariem Alwan, Mahmod Jasem Jawad, Atheer Khdyair Hamad, Hossein Gandomkar","doi":"10.1080/1061186X.2025.2489979","DOIUrl":"10.1080/1061186X.2025.2489979","url":null,"abstract":"<p><p>Cancer is a leading cause of mortality and morbidity worldwide. Nanomaterials, unique optical, magnetic, and electrical properties at the nanoscale (1-100 nm), have been engineered to improve drug capacity, bioavailability, and specificity in cancer treatment. These advancements address toxicity and lack of selectivity in conventional therapies, enabling precise targeting of cancer cells, the tumour microenvironment, and the immune system. Among emerging approaches, bacterial treatment shows promise due to its natural ability to target cancer and its diverse therapeutic mechanisms, which nanotechnology can further enhance. Bacteria-based drug delivery systems leverage bacteria's adaptability and survival strategies within the human body. Bacterial derivatives, such as bacterial ghosts (BGs), bacterial extracellular vesicles (BEVs), and dietary toxins, are recognised as effective biological nanomaterials capable of carrying nanoparticles (NPs). These systems have attracted increasing attention for their potential in targeted NP delivery for cancer treatment. This study explores the use of various bacteria and their byproducts as NP delivery vehicles, highlighting their potential in treating different types of cancer. By combining the strengths of nanotechnology and bacterial therapy, these innovative approaches aim to revolutionise cancer treatment with improved precision and efficacy.</p>","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-34"},"PeriodicalIF":4.3,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143788425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rohan Anchan, Anish Ghadi, Mohammed Ali Chauhan, Angel Godad, Sankalp Gharat
{"title":"Understanding the role of ethosomes in rheumatoid arthritis: innovative solutions to challenges in transdermal delivery of synthetic drugs and phytoconstituents.","authors":"Rohan Anchan, Anish Ghadi, Mohammed Ali Chauhan, Angel Godad, Sankalp Gharat","doi":"10.1080/1061186X.2025.2477068","DOIUrl":"10.1080/1061186X.2025.2477068","url":null,"abstract":"<p><p>Rheumatoid Arthritis (RA), an autoimmune disease, is a chronic inflammatory disorder affecting the joints leading to severe damage and cartilage destruction. Current therapies for RA such as DMARDs, NSAIDs, glucocorticoids and phytoconstituents often face challenges related to solubility and transdermal permeability. Considering the barriers posed by the stratum corneum in transdermal drug delivery, ethosomes have shown promising results in overcoming these hurdles. The presence of ethanol in ethosomes imparts flexibility and disrupts the skin's lipid bilayer, allowing for transdermal penetration. Researchers have explored the potential of ethosomal drug delivery systems loaded with various synthetic drugs and phytoconstituents for the management of RA. Despite promising preclinical findings, these systems have yet to transition from the bench to the bedside, and there is a lack of comprehensive review papers highlighting the potential of ethosomes in RA treatment. Considering the commercial challenges in scaling up such nano systems, this review aims to analyse the current state of the art and advancements in ethosomal formulations loaded with synthetic agents and phytoconstituents. Further, it explores the impact of excipients and processing parameters, on the preparation of ethosomes and their efficacy in overcoming skin barriers, to enhance the permeability of therapeutic agents.</p>","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-15"},"PeriodicalIF":4.3,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Punith M, Rajamma A J, Sateesha S B, Durgashree Diwakar, Girija E K, Chethan Kumar K B, Ankith N A, Mousam Bhowmik, Manjunatha P M
{"title":"Design and formulation of fast-dissolving microneedles for the rapid transdermal delivery of lorazepam.","authors":"Punith M, Rajamma A J, Sateesha S B, Durgashree Diwakar, Girija E K, Chethan Kumar K B, Ankith N A, Mousam Bhowmik, Manjunatha P M","doi":"10.1080/1061186X.2025.2483720","DOIUrl":"10.1080/1061186X.2025.2483720","url":null,"abstract":"<p><p>This study investigates lorazepam-loaded dissolving microneedles (LMNs) as a fast-acting and minimally invasive treatment for status epilepticus. The LMNs were developed using a micro-moulding technique with an optimised combination of PVP K30, Dextran 40 and Pullulan. Their stability was confirmed through Fourier transform infra-red (FTIR) spectroscopy and X-ray diffraction (XRD) analysis. The Parafilm<sup>®</sup> membrane insertion test demonstrated 100% penetration efficiency, verifying their ability to effectively pierce the skin. Scanning electron microscopy (SEM) imaging revealed well-defined microneedles with precise dimensions (800 µm height, 200 µm base and 500 µm pitch). The LMNs rapidly dissolved in the subdermal layer of porcine skin. An <i>ex vivo</i> drug diffusion study showed that 3-5% of the encapsulated lorazepam was released within 30 min, with a cumulative release of 79.3% over 24 h. An acute dermal irritation study confirmed the biocompatibility and skin tolerance of the LMNs. Additionally, an <i>in vivo</i> anti-convulsant efficacy study in Albino Wistar rats subjected to maximal electroshock seizures demonstrated significant anticonvulsant effects (<i>p</i> < .05), confirming efficient systemic delivery of lorazepam. These findings highlight LMNs as a rapid-acting, non-invasive transdermal drug delivery system for managing status epilepticus, particularly in ambulatory care settings.</p>","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-13"},"PeriodicalIF":4.3,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143710300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hui Wang, Shang Li, Tianqi Zhao, Xixi Pan, Liangxue Wang
{"title":"Effect of insulin aspart combined with insulin detemir and metformin on islet function in newly diagnosed type 2 diabetes mellitus.","authors":"Hui Wang, Shang Li, Tianqi Zhao, Xixi Pan, Liangxue Wang","doi":"10.1080/1061186X.2025.2477074","DOIUrl":"10.1080/1061186X.2025.2477074","url":null,"abstract":"<p><p>This trial evaluated the effects of insulin aspart (IAsp) and insulin detemir and metformin on islet function in newly diagnosed type 2 diabetes mellitus (T2DM). A total of 96 T2DM patients were randomised into the control group (insulin detemir + metformin treatment) and the study group (insulin detemir + metformin + IAsp treatment), with 48 cases each. The study compared clinical outcomes, as well as changes in fasting plasma glucose (FPG), 2-hour postprandial blood glucose (PBG), glycated haemoglobin (HbA1c), fasting insulin (FINS), homeostasis model assessment of insulin resistance (HOMA-IR), HOMA-β, quality of life, and sleep quality scores before and after treatment. Compared to the control group, the study group showed a higher total effective treatment rate, lower levels of FPG, 2-hour PBG, HbA1c, FINS, HOMA-IR, and sleep quality scores, while demonstrating higher HOMA-β and quality of life scores (all <i>p</i> < 0.05). Insulin detemir + metformin + IAsp was effective in treating T2DM, significantly enhancing insulin function and blood glucose levels, quality of life, and sleep quality. This combination therapy, though not commonly utilised in newly diagnosed T2DM patients, offers a novel therapeutic approach in clinical practice.</p>","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-5"},"PeriodicalIF":4.3,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143573224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Synergistic cancer treatment using porphyrin-based metal-organic Frameworks for photodynamic and photothermal therapy.","authors":"Mahsa Akbari Oryani, Mojtaba Tarin, Leila Rahnama Araghi, Farangis Rastin, Hossein Javid, Alireza Hashemzadeh, Mehdi Karimi-Shahri","doi":"10.1080/1061186X.2024.2433551","DOIUrl":"10.1080/1061186X.2024.2433551","url":null,"abstract":"<p><p>Recent advancements in multifunctional nanomaterials for cancer therapy have highlighted porphyrin-based metal-organic frameworks (MOFs) as promising candidates due to their unique properties and versatile applications. This overview focuses on the use of porphyrin-based MOFs for combined photodynamic therapy (PDT) and photothermal therapy (PTT) in cancer treatment. Porphyrin-based MOFs offer high porosity, tuneable structures, and excellent stability, making them ideal for drug delivery and therapeutic applications. The incorporation of porphyrin molecules into the MOF framework enhances light absorption and energy transfer, leading to improved photodynamic and photothermal effects. Additionally, the porosity of MOFs allows for the encapsulation of therapeutic agents, further enhancing efficacy. In PDT, porphyrin-based MOFs generate reactive oxygen species (ROS) upon light activation, destroying cancer cells. The photothermal properties enable the conversion of light energy into heat, resulting in localised hyperthermia and tumour ablation. The combination of PDT and PTT in a single platform offers synergistic effects, leading to better therapeutic outcomes, reduced side effects, and improved selectivity. This dual-modal treatment strategy provides precise spatiotemporal control over the treatment process, paving the way for next-generation therapeutics with enhanced efficacy and reduced side effects. Further research and optimisation are needed for clinical applications.</p>","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"473-491"},"PeriodicalIF":4.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}